Sumary of Baricitinib remains safe, effective in RA at 8.4 years:
- A long-term safety study of baricitinib for rheumatoid arthritis, with more than 13,000 patient-years of exposure, found no increase in safety issues for up to 8.4 years, according to a speaker at ACR Convergence..
- “This [study] added to prior integrated safety analyses of baricitinib by reporting on additional years of exposure,”.
- A long-term safety study of baricitinib for RA, with more than 13,000 patient-years of exposure, found no increase in safety issues for up to 8.4 years, according to Kevin Winthrop, MD, MPH..
- These included one phase 1, three phase 2 and five phase 3 trials — all completed — and one ongoing long-term extension study..
- Meanwhile, major adverse cardiovascular events were assessed in the phase 3 trials and in the long-term extension..
- Incidence rates for serious infections were analyzed by age group through week 24 for patients who received either placebo or 4 mg of baricitinib in seven phase 2 or 3 trials —identified as the “bari-RA-PC analysis set”…